OverviewSuggest Edit

Alnylam Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The Company’s pipeline focuses in three strategic therapeutic areas (STArs): genetic medicines, with a pipeline of RNAi therapeutics for the treatment of rare diseases; cardio-metabolic disease, with a pipeline of RNAi therapeutics toward genetically validated, liver-expressed disease in cardiovascular and metabolic diseases, and hepatic infectious disease, with a pipeline of RNAi therapeutics for treatment of hepatic infectious diseases.

TypePublic
Founded2002
HQCambridge, MA, US
Websitealnylam.com
Employee Ratings4.2
Overall CultureB

Latest Updates

Employees (est.) (Dec 2019)1,323(+25%)
Job Openings93
Revenue (FY, 2020)$492.9 M(+125%)
Share Price (Sept 2021)$188(+2%)
Cybersecurity ratingBMore

Key People/Management at Alnylam Pharmaceuticals

Yvonne Greenstreet

Yvonne Greenstreet

COO
Pushkal Garg

Pushkal Garg

Chief Medical Officer
Al Boyle

Al Boyle

Chief Technical Operations and Quality Officer
Laurie Keating

Laurie Keating

EVP, Chief Legal Officer and Secretary
John Maraganore

John Maraganore

CEO
Jeff Poulton

Jeff Poulton

Chief Financial Officer
Show more

Alnylam Pharmaceuticals Office Locations

Alnylam Pharmaceuticals has offices in Cambridge, Paris, Milano, Amsterdam and in 3 other locations
Cambridge, MA, US (HQ)
675 W Kendall St
Paris, FR
100 Av. de Suffren
Milano, IT
Via Pola, 11
Amsterdam, NL
Strawinskylaan 3051
Stockholm, SE
Olof Palmes gata 29
Zug, CH
Grafenauweg 4
Show all (7)

Alnylam Pharmaceuticals Financials and Metrics

Alnylam Pharmaceuticals Revenue

Alnylam Pharmaceuticals's revenue was reported to be $492.85 m in FY, 2020
USD

Revenue (FY, 2020)

492.9m

Gross profit (FY, 2020)

414.8m

Gross profit margin (FY, 2020), %

84.2%

Net income (FY, 2020)

(858.3m)

EBIT (FY, 2020)

(828.4m)

Market capitalization (14-Sept-2021)

22.1b

Closing stock price (14-Sept-2021)

188.0

Cash (31-Dec-2020)

496.6m

EV

21.9b
Alnylam Pharmaceuticals's current market capitalization is $22.1 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

100.0m74.9m219.8m492.9m

Cost of goods sold

1.8m25.1m78.1m

Gross profit

73.1m194.7m414.8m

Gross profit Margin, %

98%89%84%
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

26.6m27.7m20.9m29.9m2.1m33.3m44.7m46.1m99.5m77.5m99.2m

Cost of goods sold

137.0k3.3m4.3m13.3m

Gross profit

1.9m29.9m40.4m86.2m

Gross profit Margin, %

93%90%90%87%
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

74.6m70.2m51.4m53.2m75.2m180.9m193.6m645.4m420.1m547.2m496.6m

Accounts Receivable

3.5m1.5m104.0k4.2m39.9m8.3m17.9m34.0m18.8m43.0m102.4m

Prepaid Expenses

4.2m2.5m3.9m9.7m16.6m40.1m73.7m80.3m62.8m

Inventories

21.7m24.1m56.3m75.2m
USDQ2, 2010

Financial Leverage

2.7 x
Show all financial metrics

Alnylam Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

89/100

SecurityScorecard logo

Alnylam Pharmaceuticals Online and Social Media Presence

Embed Graph

Alnylam Pharmaceuticals Company Culture

  • Overall Culture

    B

    72/100

  • CEO Rating

    A+

    87/100

  • Compensation

    A+

    89/100

Learn more on Comparably

Alnylam Pharmaceuticals Blogs

RNAi Roundtable: Liver-Directed RNAi Pipeline Programs

On September 20, 2021, we hosted an online RNAi Roundtable to review the progress with our liver-directed RNAi pipeline programs. Access the replay View the presentation Eric Green Senior Vice President, Development Programs Tanya Fischer, M.D., Ph.D. Vice President, Clinical Development Josh Friedm…

New Results from the OXLUMO® (lumasiran) Clinical Program Presented at AUA Annual Meeting

New kidney stone data from ongoing clinical trials of OXLUMO® (lumasiran), an RNAi therapeutic targeting hydroxyacid oxidase 1 – the gene encoding glycolate oxidase – for the treatment of primary hyperoxaluria type 1 (PH1), were presented at the American Urological Association (AUA) Annual Meeting, …

New Results for Vutrisiran at EU-ATTR Amyloidosis Meeting

Additional positive 9-month results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis with polyneuropathy, were presented at the 3rd EU-ATTR A…

RNAi Roundtable: Lumasiran, for the Treatment of Primary Hyperoxaluria Type 1

On August 19, 2021, we hosted an online RNAi Roundtable to review the progress with lumasiran, for the treatment of primary hyperoxaluria type 1. Access the replay View the presentation Jerome Valkenburg, MS, MScBA Sr. Director & Program Lead, Lumasiran Jeffrey M. Saland, M.D., MSCR... The post …

RNAi Roundtable: Zilebesiran (ALN-AGT), in Development for the Treatment of Hypertension

On June 30, 2021, we hosted an online RNAi Roundtable to review the progress with zilebesiran (ALN-AGT), an RNAi therapeutic in development for the treatment of hypertension. Access the replay View the presentation Pushkal Garg, M.D. Chief Medical Officer Elizabeth Ofili, M.D., MPH, FACC Professor..…

Eighth Annual RNAi Roundtable Series

We are hosting a series of online “RNAi Roundtables” at which Alnylam scientists and program leaders, as well as medical thought leaders, will review recent progress in many of our pipeline programs and platform, and provide perspectives on clinical developments and unmet needs in various... The pos…
Show more

Alnylam Pharmaceuticals Frequently Asked Questions

  • When was Alnylam Pharmaceuticals founded?

    Alnylam Pharmaceuticals was founded in 2002.

  • Who are Alnylam Pharmaceuticals key executives?

    Alnylam Pharmaceuticals's key executives are Yvonne Greenstreet, Pushkal Garg and Al Boyle.

  • How many employees does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 1,323 employees.

  • What is Alnylam Pharmaceuticals revenue?

    Latest Alnylam Pharmaceuticals annual revenue is $492.9 m.

  • What is Alnylam Pharmaceuticals revenue per employee?

    Latest Alnylam Pharmaceuticals revenue per employee is $372.5 k.

  • Who are Alnylam Pharmaceuticals competitors?

    Competitors of Alnylam Pharmaceuticals include Reata Pharmaceuticals, Celyad and Sorrento Therapeutics.

  • Where is Alnylam Pharmaceuticals headquarters?

    Alnylam Pharmaceuticals headquarters is located at 675 W Kendall St, Cambridge.

  • Where are Alnylam Pharmaceuticals offices?

    Alnylam Pharmaceuticals has offices in Cambridge, Paris, Milano, Amsterdam and in 3 other locations.

  • How many offices does Alnylam Pharmaceuticals have?

    Alnylam Pharmaceuticals has 7 offices.